Key clinical point: Men with metastatic breast cancer (MBC) have a similar prognosis, compared with women, but gonadal suppression remains a topic of debate.
Major finding: Median PFS was 9.8 months in men, compared with 13.0 months in matched women.
Study details: The ESME study was a large-scale retrospective analysis of 16,701 patients, 149 of whom were men with MBC. Male-GBG54 was a prospective, randomized trial involving 46 MBC patients who received three different endocrine therapies.
Disclosures: Discussant Dr. Schroeder disclosed financial relationships with Novartis, Roche, Genentech, and others. Male-GBG54 was funded by Claudia von Schilling Foundation.
Sirieix et al. ESMO 2018, Abstract 294PD; Reinisch et al. ESMO 2018, Abstract 273PD.